Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2026-05-07 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
国新证券股份有限公司关于云南生物谷药业股份有限公司向不特定合格投资者公开发行股票保荐工作总结报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Guoxin Securities Co., Ltd. acting as the sponsor for Yunnan Biological Valley Pharmaceutical Co., Ltd. regarding the public offering of shares to qualified investors. It includes comprehensive information about the company's background, the sponsor's due diligence and continuous supervision work, major events during the sponsorship period such as fund occupation by the original controlling shareholder, regulatory penalties, project delays, changes in controlling shareholders due to judicial auctions, and changes in sponsor representatives. The document is titled as a "Sponsorship Work Summary Report" and contains substantive content about the sponsor's responsibilities and findings, not just an announcement or a brief summary. It is not a typical financial report like an annual or interim report, nor is it a regulatory filing or announcement. It is a specialized report related to capital market activities, specifically the sponsorship and supervision of a public stock issuance. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length (5975 characters) and detailed content support this classification with high confidence.
2026-05-07 Chinese
国新证券股份有限公司关于云南生物谷药业股份有限公司2025年年度持续督导跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2025年度持续督导跟踪报告" (2025 Annual Continuous Supervision Follow-up Report) issued by the sponsor institution (国新证券股份有限公司) for the company 云南生物谷药业股份有限公司. It details the sponsor's supervision activities, findings, and measures taken regarding the company's compliance, financial status, and governance. The content includes detailed supervisory work, issues found, company and shareholder commitments, and other matters related to ongoing regulatory oversight. It is not a full annual report (10-K), nor an earnings release or audit report. It is a specific regulatory continuous supervision report required by securities regulations in China, which fits the category of Audit Report / Information (AR) as it is a standalone regulatory supervisory report rather than a full annual report or other category. The document length is 4007 characters, which is consistent with a detailed report rather than a brief announcement or certification. Therefore, the best classification is AR (Audit Report / Information). FY 2025
2026-05-07 Chinese
2025年度独立董事述职报告（于团叶）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report for 2025" from a specific independent director of the company. It details the director's background, independence, attendance at board and committee meetings, exercise of duties, communication with auditors and shareholders, and overall evaluation and suggestions for the company. The content focuses on the director's duties and activities during the year rather than presenting financial statements or audit results. It is a detailed report on board/management information, specifically about the independent director's role and activities. There is no indication that this is an annual report (10-K), audit report (AR), or other financial report. The document is not a brief announcement or a proxy statement but a substantive report on board/management matters. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (6028 characters) supports it being a full report rather than a short announcement.
2026-04-27 Chinese
拟续聘2026年度会计师事务所公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (信永中和会计师事务所) as the auditor for the fiscal year 2026. It details the auditor's background, integrity record, audit fees, and the approval process by the board and audit committee. There are no actual financial statements or audit reports included, only information about the auditor appointment and related procedures. The document length is 3390 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information (AR) type, since it relates to audit matters but is not a full annual report or financial statement. However, given the document is primarily an announcement of auditor reappointment and related information, it fits the Audit Report / Information category rather than a full Annual Report or Regulatory Filing. Confidence is high due to clear content focus on audit firm reappointment and audit-related disclosures. FY 2026
2026-04-27 Chinese
信永中和会计师事务所关于云南生物谷药业股份有限公司2025年度非经营性资金占用及其他关联资金往来的专项说明
Audit Report / Information Classification · 95% confidence The document is titled as a "专项说明" (special explanation) regarding non-operating fund occupation and other related party fund transactions for the fiscal year 2025 of Yunnan Biological Valley Pharmaceutical Co., Ltd. It includes a summary table of related party fund transactions and is accompanied by an auditor's statement from ShineWing Certified Public Accountants. The auditor confirms that the data in the special explanation is consistent with the audited 2025 financial statements and that the explanation is prepared according to regulatory requirements from the China Securities Regulatory Commission and Beijing Stock Exchange. The document is not a full annual report (10-K) or interim report, but a specific audit-related explanatory report focusing on related party transactions and fund occupation, with an auditor's attestation. It is a standalone audit-related report, not a general regulatory filing or announcement. Therefore, it fits best under the category of Audit Report / Information (AR). The document length (5591 characters) supports it being a substantive report rather than a brief announcement. Confidence is high given the detailed audit content and regulatory references. FY 2025
2026-04-27 Chinese
董事会审计委员会2025年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as a "董事会审计委员会2025年度履职情况报告" which translates to "Board Audit Committee 2025 Annual Performance Report." It details the audit committee's activities, meetings, oversight of financial reports, external audit supervision, internal audit guidance, and internal control evaluation for the year 2025. The document is a report on the audit committee's duties and performance rather than a full annual report or standalone audit report. It is not a short announcement or certification but a substantive report on audit committee activities. This fits best under the category of Audit Report / Information (AR), which includes reports on audit results and applied accounting principles, excluding full annual reports. The document length (2657 characters) is relatively short but contains detailed audit committee information and evaluations, consistent with AR rather than a mere announcement or certification. Therefore, the classification is AR with high confidence. FY 2025
2026-04-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.